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1.  Introduction 
 
1.1  Background 
Malaria poses a tremendous public health problem across the globe with an estimated 40% of 
the world‘s population living in areas of malaria risk [1].  An estimated 190–330 million malaria 
episodes and at least 1 million malaria deaths occur annually [2].  While malaria is endemic 
within most tropical and subtropical regions of the world, 90% of all malaria deaths currently 
occur in sub-Saharan Africa (SSA) [3].  Young children and pregnant women represent those at 
greatest risk of malaria-related morbidity and mortality, especially in areas of stable 
transmission. It has recently been estimated that malaria is responsible for approximately 20% 
of all deaths among children less than 5 years of age in SSA [4].  Malaria also places an 
enormous toll on the already overburdened health systems across SSA and elsewhere, as it 
has been estimated that malaria-related illnesses account for approximately 30% of all 
outpatient clinic visits within malaria-endemic countries of the SSA region [5].  
 
The last 10 years have seen a resurgence of interest in malaria as a disease of major public 
health importance. To coordinate the efforts of the international community, the Roll Back 
Malaria (RBM) partnership was launched in 1998, with the goal of halving the burden of malaria 
by 2010.  Under the auspices of RBM, the heads of state from across Africa met in Abuja, 
Nigeria in 2000 to express their commitment to combating malaria and established the first set 
of concrete, measurable goals for national malaria control strategies. As part of the Roll Back 
Malaria Partnership, the United Nations family of organizations has also emphasized malaria 
control in recent initiatives. The UN declared 2001–2010 the ―Decade to Roll Back Malaria‖ in 
developing countries, particularly in Africa, and set malaria as a high priority within the United 
Nations (UN) Millennium Development Goals.  In May 2002, the strategies for protecting 
children and pregnant women from malaria were also adopted by the UN General Assembly‘s 
Special Session on Children (A World Fit for Children).  
 
In order to respond to the medical, public health, and economic burden of this disease, 
international funding for malaria control has greatly increased over the last several years [6].  
The Global Fund to Fight AIDS, Tuberculosis, and Malaria was created in 2002 and has 
committed over $1.7 billion for malaria programs in over 76 recipient countries between 2002 
and 2007.  In 2005, both the World Bank‘s Malaria Control Booster Program and the U.S. 
President‘s Malaria Initiative (PMI) were established.  The Booster program reflects an eight-fold 
increase in World Bank malaria funding in Africa, and the PMI is a $1.2 billion five year initiative 
coordinated with national malaria control programs.  Additionally, the Bill and Melinda Gates 
Foundation committed $83.5 million in new malaria grants in 2006, which will support malaria 
prevention and treatment programs as well as research and development [7]. RBM Working Group                                                              TECHNICAL PAPER – RBM/WG/2009/TP.1 
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Table 1: 
RBM Technical Strategies, Associated RBM Global Strategic Plan and PMI Targets, and 
MDG Goal and Indicators 
Overall Goal  Roll Back Malaria 
Partnership 
 
President’s Malaria 
Initiative 
Millennium Development 
Goal 
Impact Target to be 
Assessed 
Halve malaria burden 
between 2000 and 2010 
50% reduction in 
malaria mortality in 15 
focus countries during 
five year period (2005-
2010) 
 
To halt and begin to 
reverse the incidence of 
malaria by the target 
date of 2015 
RBM Technical 
Strategies 
RBM Global Strategic 
Plan Targets (by 2010) 
 
PMI Coverage Targets 
(by 2010) 
MDG Indicators 
Vector control via 
insecticide-treated 
nets (ITNs) 
80% of people at risk 
from malaria are using 
locally appropriate vector 
control methods such as 
long-lasting insecticidal 
nets (LLINs), indoor 
residual spraying (IRS) 
and, in some settings, 
other environmental and 
biological measures 
 
85% of children under 
five and pregnant 
women will have slept 
under an ITN the 
previous night 
Incidence and death 
rates associated with 
malaria 
Prompt access to 
effective treatment 
80% of malaria patients 
are diagnosed and 
treated with effective 
anti-malarial treatments 
85% of children under 
five with suspected 
malaria will have 
received treatment with 
ACTs within 24 hours 
of onset of their 
symptoms 
Proportion of children 
under 5 sleeping under 
insecticide-treated 
bednets 
Prevention and 
control of malaria in 
pregnant women 
In areas of high 
transmission, 100% of 
pregnant women receive 
IPT 
85% of women who 
have completed a 
pregnancy in the last 
two years will have 
received two or more 
doses of IPT during 
that pregnancy 
 
Proportion of children 
under 5 with fever who 
are treated with 
appropriate anti-malarial 
drugs 
Adapted Breman 2007, PMI Second Annual Report and RBM Global Strategic Plan, 2005-2015 [3, 8, 9]  
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This increase in available resources has allowed endemic countries to rapidly increase 
coverage of malaria interventions.  With this scale-up of control efforts, national monitoring and 
evaluation systems must be strengthened in order to ensure that such implementation efforts 
are as effective as possible.  Furthermore, an effective system for monitoring progress and 
evaluating results will be critical for assessing the effectiveness of control strategies.  Such data 
will be crucial for identifying areas where modifications in specific technical strategies may be 
needed, as well as where resources should be focused.  To facilitate this process, the RBM 
partners have established a set of core indicators that can be collected through household 
surveys that permit national-level monitoring and evaluation of the technical strategies 
supported by RBM. 
 
In addition, the recent calls for eradication and elimination will require increased vigilance for 
monitoring and evaluation systems. Routine surveys will continue to play an important role in 
monitoring sustained coverage of key interventions. Facility-based surveillance systems will 
need to be improved to track, diagnose and treat cases rapidly and effectively. National 
laboratory systems will be important to identifying imported versus indigenous cases and 
monitor parasite species mix. These and other refinements of national monitoring and 
evaluation systems will be critical to maintaining high levels of malaria control and tracking 
progress towards elimination and eventual eradication.  
 
1.2  Purpose and Content of Manual 
The purpose of this manual is to provide country partners with technical guidance on the 
detailed specifications of the core indicators that can be measured through household surveys, 
the data required for their construction, as well as issues related to their interpretation.  Details 
of the data collection methods required for estimating these indicators through national-level 
household surveys are also provided.  This manual is intended to maximize internal consistency 
and comparability of the indicators across countries and over time, and to ensure consistency in 
the types of data collection methods used. 
 
It should be noted that the indicators and measurement tools described in this guide were 
developed in the context of the high malaria burden countries of Africa, where malaria is a 
generalized problem and programs target the segments of the population that are at greatest 
risk such as children under 5 and pregnant women. In other settings, such as South East Asia 
and Latin America, a more targeted approach to monitoring and evaluation is necessary and the 
use of large, nationally representative surveys to measure coverage may not be necessary or 
may be deployed less frequently. Likewise, the indicators to measure programs such as 
Insecticide-Treated Net (ITN) use, or Intermittent Preventative Treatment (IPT) in pregnant 
women, may not reflect the strategies used in Asia and Latin America. This guide specifically 
focuses on Africa because of the critical need to track the scale up of key interventions and 
provide evidence of their impact in this region of highest disease burden and greatest 
investment in malaria control. Guidance for the types of programs supported in other regions, 
such as drug efficacy/quality, and access to treatment for marginalized populations, will be dealt 
with in other publications. 
 
This manual begins with a brief discussion on the basic principles of monitoring and evaluation.  
The outcome indicators that will be used to measure the success of the RBM technical 
strategies of ITNs, indoor residual spraying (IRS), prompt access to effective treatment, and RBM Working Group                                                              TECHNICAL PAPER – RBM/WG/2009/TP.1 
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prevention and control of malaria in pregnant women are then listed.  A brief discussion on the 
rationale for these RBM technical strategies is also provided.  Next, three impact indicators are 
listed, followed by an explanation regarding the need for both morbidity and mortality measures.  
Discussions on measurement tools, methods of measurement, interpretation, and reporting of 
the indicators are then provided.  The manual concludes with detailed guidelines for 
constructing each indicator. 
 
Due to increased funding in the past few years, malaria control efforts have expanded rapidly 
and interventions have evolved with the changing funding climate.  Therefore, the guidelines 
presented in this updated manual have changed substantially from those previously published in 
2006.  Notable changes include — 
 
  An additional coverage indicator to assess the roll-out of diagnostic programs. 
  An additional coverage indicator which provides a measure of the proportion of 
households covered by one or both of the two main vector control interventions, ITNs and 
IRS, now being used. 
  The inclusion of three impact indicators: all-cause under 5 mortality, parasitemia 
prevalence among under 5 year olds, and anemia prevalence among under 5 year olds. 
It should also be noted that in this version, many of the indicator descriptions in Section 4 are 
followed by a text box, which includes either a supplemental indicator or secondary analyses 
that may be appropriate to report under certain circumstances.  The supplemental indicators 
may include a broader age group than the related core indicator, may be derived using different 
methods, or may be obtained from a data source other than household surveys (e.g. HMIS or 
program reports).  The supplemental indicators obtained from other data sources may be 
necessary to measure the program coverage of a given intervention, as opposed to the national 
coverage which is measured by large-scale household surveys.  For example, IRS program 
coverage may be more appropriate to measure in countries where spraying is not conducted 
throughout the entire country.  While none of these indicators are being recommended as core 
indicators by the RBM partners, certain countries may find them pertinent and therefore 
information regarding their utility and comparability has been included.    RBM Working Group                                                              TECHNICAL PAPER – RBM/WG/2009/TP.1 
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2.  Monitoring and Evaluation 
 
Evaluation is the use of social or epidemiological research methods to assess, and ideally 
improve, the implementation of public health programs.  The overall goal of monitoring and 
evaluation (M&E) is to measure program effectiveness.  M&E may be focused on local initiatives 
as well as measuring program effectiveness at the national and regional levels.  Ideally, M&E 
tools can be used to demonstrate to planners and other decision-makers that program efforts 
have had measurable impacts on the outcomes of interest.  M&E can also provide insight as to 
where resources are being used most efficiently versus where new strategies should be 
considered.  
 
Monitoring is used to verify step-by-step the progress of malaria control programs at various 
levels to see whether activities have been implemented as planned, ensure accountability, 
detect problems and constraints related to the intervention activities, and promote evidence-
based planning through timely feedback to the relevant authorities.  Indicators of inputs, 
processes, and outputs are typically used for monitoring purposes at the program level.  Input 
indicators are generally used to measure the level of resources available for use by the program 
or intervention, such as the funding obtained to purchase ITNs.  Process indicators are 
generally used to verify that a program or intervention has been implemented as planned, such 
as verifying that ITNs have been purchased and are ready for distribution.  It is expected that 
inputs and desired processes will lead to desired changes in output indicators, which are 
generally used to measure benchmarks of program-level performance, such as the number of 
ITNs distributed to a particular target population.  Figure 1 provides an example schematic of 
the level and function of indicators typically used for M&E. 
 
While monitoring is a continuous process, formal evaluation is required to determine and 
document the extent to which any expectant results are attributable to a particular malaria 
control program, as measured through outcome and impact indicators.  Outcome indicators are 
generally used to measure medium-term population-level results, such as the level of ITN 
coverage among a particular target population that can be attributed to an ITN program or 
intervention.  It is expected that desired changes in outcomes will lead to a desired impact, 
which generally refers to the overall, long-term goals of a program or initiative, such as the RBM 
goal of halving malaria-related morbidity and mortality by 2010.  
 
Impact measurement is the ultimate goal, and often the most challenging aspect, of program 
evaluation, and this is particularly the case for malaria. True impact evaluation involves 
measuring changes in impact level indicators, such as morbidity and mortality, and empirically 
linking the observed change with a specific program or intervention. This type of evaluation 
requires rigorous experimental design to make a causal association between program inputs 
and the resulting impact measures. In the field of public health, where programs operate in the 
context of existing communities and not in controlled trial settings, evaluators rarely have this 
luxury. In addition, malaria-specific morbidity and mortality are very difficult to measure even in 
the best of situations. The signs and symptoms of malaria illness are non-specific and mimic 
many other childhood illnesses. Even with modern diagnostic tests (microscopy/RDT), the 
sensitivity and specificity of the tests can vary in different study settings. Malaria-specific 
mortality is even more difficult to measure given that most deaths occur in the home and 
definitive cause of death is not usually available.  
 RBM Working Group                                                              TECHNICAL PAPER – RBM/WG/2009/TP.1 
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For these reasons, the RBM Partnership places a strong emphasis on measuring changes in 
population-level coverage of the core indicators at the outcome level. There is substantial 
empirical evidence to support the efficacy of current technical strategies in different 
programmatic contexts. It is expected that increasing coverage of these key interventions will 
result in the desired reductions in morbidity and mortality. Therefore, it is crucial that countries 
implementing these interventions have clear definitions and appropriate tools for measuring the 
outcome indicators for population-level coverage as part of their overall monitoring and 
evaluation strategy.  In addition, this guide provides basic information for measuring impact 
indicators, in order to allow countries to assess whether scale-up of the key interventions has 
resulted in the intended impact at the population level over the longer term. 
 
 
 
Figure 1:  
 
Level and Function of M&E Indicators 
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Indicators for evaluating results  
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measured at the population level 
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3.  Core Indicators for Evaluating RBM Technical Strategies 
 
3.1  Core Outcome Indicators 
There are eight outcome indicators that will be used to measure the proportion of the population 
that is covered by the interventions outlined by the RBM technical strategies, as shown in Table 
2. It is recognized that certain interventions, such as IPT and IRS, are not ongoing malaria 
control activities conducted outside of the African region, so certain indicators may not be 
pertinent to all RBM partner countries. 
Table 2: 
Indicators of Population Coverage for Evaluating RBM Technical Strategies 
RBM Intervention  Indicator Description 
Insecticide-treated nets (ITNs) and 
indoor residual spraying (IRS) 
1.  Proportion of households with at least one ITN. 
 
2.  Proportion of children under 5 years old who slept under 
an ITN the previous night. 
 
3.  Proportion of Households with at least one ITN and/or 
sprayed by IRS in the last 12 months. 
 
4.  Proportion of children under 5 years old with fever in last 
2 weeks who received any antimalarial treatment. 
 
Prompt and effective treatment and 
use of diagnostics 
 
5.  Proportion of children under 5 years old with fever in last 
2 weeks who received antimalarial treatment according to 
national policy within 24 hours from onset of fever. 
 
6.  Proportion of children under 5 years old with fever in the 
last 2 weeks who had a finger or heel stick. 
 
Prevention and control of malaria in 
pregnant women 
7.  Proportion of pregnant women who slept under an ITN 
the previous night. 
 
8.  Proportion of women who received intermittent preventive 
treatment for malaria during ANC visits during their last 
pregnancy. 
 
 
 RBM Working Group                                                              TECHNICAL PAPER – RBM/WG/2009/TP.1 
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Insecticide-treated Nets and Indoor Residual Spraying 
 
Under trial conditions, ITNs have been shown to reduce malaria transmission by as much as 
90% [10], with concomitant reductions in malaria-related morbidity [11, 12].  Community 
randomized controlled trials have also shown ITNs to be associated with significant reductions 
in all-cause under 5 child mortality by as much as a third, across a range of malaria 
transmission settings in SSA [13, 14].  ITNs have also been shown to remain effective under 
field conditions, as it was shown that social marketing of ITN in Tanzania was associated with a 
27% increase in survival, as well as 65% reduction in anemia, among children 1 month to 4 
years old [15].  Efforts to scale up coverage of ITNs are underway in most African countries and 
are greatly assisted by efforts to remove associated taxes and tariffs on imported commodities 
[16].  
 
IRS is the organized, timely spraying of an insecticide on the inside walls of houses or 
dwellings. It is designed to interrupt malaria transmission by killing adult female mosquitoes 
when they enter houses and rest on the walls after feeding, but before they can transmit the 
infection to another person [17].  IRS has been shown to be effective in reducing vectorial 
capacity and malarial disease in a wide variety of settings, and is particularly effective in 
locations where mosquitoes are indoor-resting and malaria is seasonally transmitted [18]. 
A coverage indicator is included to measure the proportion of households covered by either an 
ITN or by IRS.  This indicator has been developed to address concerns regarding the small 
areas or ‗target zones‘ that are sprayed with IRS in many countries, and the potential 
misinterpretation of a national-level IRS indicator that may result.  By including ITN and IRS 
interventions in a single indicator, one can assess overall coverage of preventive control 
measures within the country. 
Prompt Access to Effective Treatment and Use of Diagnostics 
 
It is widely recognized that access to prompt and effective treatment is a key element in 
successful malaria control because of the rapid onset of illness and severe health outcomes 
related to Plasmodium falciparum malaria, especially among children and non-immune 
populations [16, 19].  However, antimalarial drug-resistance has become a major challenge in 
providing an effective malaria treatment within many regions of the world. Resistance to 
traditional monotherapies such as chloroquine, sulfadoxine-pyrimethamine, and amodiaquine, is 
now widespread across most of Africa.  As a result, the World Health Organization now 
recommends treating malaria using artemisinin-based combination therapies (ACTs) ([7].  
Understanding which antimalarial drugs are provided to children for fever, and the promptness 
with which they are received after the onset of symptoms, at the community level is an important 
component for monitoring prompt access to effective treatment. 
 
The replacement of conventional antimalarial drugs with high-cost, artemisinin-based 
alternatives has created an increased need for accurate disease diagnosis. In addition to 
avoiding unnecessary treatment with these expensive drug combinations, diagnostics allow a 
more rational use of drugs that might effectively reduce drug pressure, thereby delaying the 
onset of drug resistance [20].  Consequently, baseline levels of diagnostic use and assessment 
of program scale-up needs to be measured during regularly conducted household surveys.  
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Prevention and Control of Malaria in Pregnant Women  
 
Malaria infection during pregnancy is a major public health concern among adult populations 
across malaria endemic areas with stable transmission, such as tropical Africa.  Malaria during 
pregnancy can result in poor outcomes for the woman and her newborn, such as maternal 
anemia, low birth weight, and premature delivery [21].  Low birth weight is the single greatest 
risk factor for neonatal mortality and a major contributor to infant mortality [22, 23].  This 
increased risk of adverse outcomes for mothers and their newborns is typically greatest for the 
mother‘s first two pregnancies.  However, in the presence of HIV infection, the risk associated 
with placental malaria appears to be independent of the number of pregnancies [24].  
 
Effective strategies for preventing and controlling malaria during pregnancy, such as the use of 
ITNs and IPT, have been shown to have a dramatic impact on the health of mothers and their 
newborns within areas of stable malaria transmission.  ITN use has been shown to significantly 
reduce the prevalence of low birth weight deliveries, as well as malaria-related morbidity among 
pregnant women [16, 25].  At present, the standard IPT regimen is a therapeutic dose of 
sulfadoxine-pyrimethamine (SP) given at least twice after quickening to all pregnant women 
during routine antenatal care.  IPT in two doses of SP during pregnancy has been shown to 
significantly reduce the prevalence of anemia and placental malaria infections at the time of 
delivery [26-28].  However, to achieve optimal benefit in settings with HIV prevalence in 
pregnant women of greater than 10%, it may likely be more cost effective to treat all women with 
a 3-dose regimen than to screen for HIV and provide this regimen only to HIV positive women 
[29].  
 
SP efficacy for treatment of symptomatic malaria in children has declined in the last five years, 
raising concerns about its longevity for IPT during pregnancy.  Consequently, studies are under 
way to determine the safety and efficacy of SP-IPTp, given the recent increase in SP resistance 
[30].  To date, SP has been shown to remain effective in this population of women, due to their 
substantial systemic immunity resulting from repeated exposure in the past.  Consequently, 
even in settings where resistance has been observed, SP continues to provide substantial 
benefit to pregnant women [31].  Any subsequent changes to the WHO recommendations will 
be incorporated into future versions of this document and communicated as needed. 
 
3.2  Core Impact Indicators 
This updated version of the RBM core indicator guidelines also includes three impact indicators, 
as shown in Table 3.  At a minimum, the RBM partners recommend that all countries with high-
intensity malaria transmission regularly monitor all-cause under 5 mortality based on data from 
statistically-sound national-level household surveys, such as Demographic and Health Surveys 
(DHS) and Multiple Indicator Cluster Surveys (MICS) [32].  
 
Alongside data on mortality, it is recommended that countries also collect data on anemia and 
parasitemia to assess malaria morbidity among children under the age of five.  Parasitemia 
prevalence is a useful morbidity indicator, as it is malaria-specific and can provide a rough 
measure of transmission [33].  Additionally, anemia prevalence is a reliable indicator of malaria 
morbidity that can reflect the impact of malaria interventions [34, 35].  The standard Malaria 
Indicator Survey (MIS) includes anemia and parasitemia biomarker measurements.  The DHS 
also routinely collects anemia data from nationally representative samples. RBM Working Group                                                              TECHNICAL PAPER – RBM/WG/2009/TP.1 
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Table 3:  
Indicators for Evaluating Impact of RBM Technical Strategies 
RBM Impact Measures  Indicator Description 
Mortality Indicator  9.  All-cause under 5 mortality rate (5q0). 
Morbidity Indicators  10.  Parasitemia Prevalence: proportion of children aged 6-59 
months with malaria infection. 
11.  Anemia Prevalence: proportion of children aged 6-59 
months with a hemoglobin measurement of <8 g/dL 
 
To evaluate impact, the RBM recommendation is to assess all-cause childhood mortality trends 
over a clearly defined time interval, and changes in malaria intervention coverage, the 
prevalence of other factors influencing malaria and non-malaria childhood mortality (vaccination 
coverage, malnutrition, etc), and morbidity indicators (anemia and parasitemia prevalence) are 
to be measured over the same time intervals to which the all-cause childhood mortality trends 
apply.  If statistically significant reductions in mortality and morbidity are found and malaria 
intervention coverage has increased to high levels and other factors influencing all-cause 
childhood mortality have not changed substantially, then it is a plausible conclusion that malaria 
control activities caused or contributed to reductions in malaria-associated mortality.  A more 
detailed description of this general evaluation method and its incorporation of a plausibility 
argument have recently been described elsewhere [36]. 
 
Countries are also advised to use coverage estimates of key malaria control interventions as 
inputs to the Lives Saved Tool (LIST), which is a user-friendly software package developed by 
the Child Health Epidemiology Reference Group (CHERG).  Based on these inputs, the model 
can predict the impact of malaria control programs on mortality among African children.  Finally, 
verbal autopsies attached to household surveys may be able to provide information on malaria-
specific mortality.  However, operational research is needed to determine the validity of data 
collected using this tool before it can be recommended.  
 
3.3  Measurement Tools 
Nationally representative, population-based sample surveys are the principal measurement 
tools required to collect the necessary data for constructing all eight core outcome indicators, as 
well as the three core impact indicators.  Three large survey efforts that currently collect data on 
malaria are the DHS, the MICS, and the MIS. 
Demographic and Health Surveys: The DHS surveys are nationally representative, 
population-based sample surveys that are routinely undertaken in many countries of SSA every 
4-5 years to collect data on a wide variety of demographic and health indicators.  Importantly, 
the DHS surveys are designed to produce data that are comparable over time and across 
countries.  The DHS survey includes a household register for the ascertainment of the age, sex, 
and relationship to the head of household for all individuals within selected households.  The 
DHS surveys are typically designed to provide relatively precise population-level estimates by 
age groups, sex, urban/rural residence, and regions.  The DHS survey package includes an 
optional module for malaria that allows the collection of necessary data for the construction of  
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the RBM core indicators.  Published reports, questionnaires, and materials related to the DHS 
surveys can be found online at http://www.measuredhs.com. 
Multiple Indicator Cluster Surveys: The MICS surveys are nationally representative, 
population-based sample surveys developed by the United Nations Children Fund (UNICEF) to 
support countries in filling critical data gaps for monitoring the situation of children and women. 
Initially designed to collect indicators marking progress toward the World Summit for Children 
goals, the MICS surveys have continued to be an important component of national data 
collection in many countries.  The MICS surveys are conducted in rounds approximately every 
three years, and since its inception in 1995, nearly 200 surveys have been conducted in 
approximately 100 countries worldwide.  Importantly, the MICS surveys are designed to produce 
data that are comparable over time and across countries, and are harmonized with data 
collected through other major household survey programs, such as DHS and MIS. The MICS 
survey package includes an optional module for malaria that allows the collection of necessary 
data for the construction of the RBM core indicators, with the exception of ITN use among 
pregnant women.  Published reports, questionnaires, and datasets related to the MICS surveys 
can be found online at http://www.childinfo.org.  
 
Malaria Indicator Survey (MIS): In addition to these ongoing survey efforts, the RBM partners 
have developed a standard MIS survey package for assessing the key household coverage 
indicators and morbidity indicators. This includes a core questionnaire and data tabulation plan, 
as well as related materials for organizing and conducting fieldwork.  This stand-alone survey is 
designed to be implemented in a similar manner to the DHS surveys, producing nationally 
representative, population-based data from which the core RBM indicators can be constructed.  
The MIS survey will also produce a wide range of data for in-depth assessment of the malaria 
situation within countries.  The MIS survey questionnaire and other related materials can be 
found online at http://www.rbm.who.int/merg.html.  
 
It is recommended that the eleven core RBM indicators be measured using either the DHS or 
MICS surveys because of their sampling design rigor and reliability over time and across 
countries.  Furthermore, a comprehensive package of demographic data is collected during both 
of these surveys, which allows additional analyses to be conducted.  However, these surveys 
are only implemented every 3-5 years.  If immediate data collection is required that does not fit 
within the implementation schedule of either the DHS or MICS surveys within a particular 
country, it is recommended that the MIS survey be used to obtain the necessary data for 
measuring the core RBM indicators.  This will ensure their comparability with the DHS and 
MICS surveys over time and across countries.  
 
3.4  Method of Measurement and Data Collection 
There are several general issues pertaining to method of measurement and data collection that 
are relevant to all eleven core indicators.  As stated, it is recommended that the data used for 
constructing the core indicators be measured through nationally representative household 
sample surveys, such as the DHS, MICS, or MIS surveys.  However, to remain consistent with 
global targets, the coverage indicators are intended to be measured among the population ―at 
risk for malaria,‖ which in some instances may create implications for survey design. 
 RBM Working Group                                                              TECHNICAL PAPER – RBM/WG/2009/TP.1 
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To ensure that standard statistical methods can be used to estimate the core indicators and 
their accompanying standard errors, it is recommended that scientific sampling procedures 
follow similar methods to those used by the DHS, MICS, or MIS surveys.  Such procedures 
typically entail a two-stage cluster sampling design with primary sampling units selected with 
probability proportional to size.   
Additionally, these samples are typically stratified by region, and by urban/rural residence, as 
stipulated by survey objectives.  For further details of this general type of sampling method, 
please refer to the sampling guidelines for the DHS, MICS, or MIS surveys, which can be found 
online at: http://rbm.who.int/merg.html.  
 
Both the DHS and MICS surveys typically include all primary sampling units for an entire 
country in their sampling frames to ensure nationally representative estimates.  In countries with 
endemic or epidemic-prone malaria throughout, it is appropriate to include all primary sampling 
units within the country in the sampling frame, given that pre-stratification by urban and rural 
residence is also undertaken, as is the case with the DHS and MICS surveys.  If a DHS or MICS 
survey is to be used for obtaining the core indicators within countries with defined areas without 
endemic or epidemic-prone malaria, such as those with mountainous areas or deserts, it should 
be noted that national estimates will include populations not at risk for malaria. This will need to 
be taken into account when interpreting national-level indicators for some countries.  Please 
refer to the MIS Sampling Guidelines for a more detailed description of how best to construct a 
sampling frame for countries with widely varying levels of malaria endemicity available at: 
http://rbm.who.int/partnership/wg/wg_monitoring/docs/mis2005/cc8.pdf. 
 
3.5  Interpretation 
There are two particular issues that will likely affect the interpretation of all eleven core RBM 
indicators to be obtained from household surveys.  
Malaria Endemicity 
 
The first issue that may affect the interpretation of the core indicators involves the definition of 
the target population.  As stated previously, the RBM targets stipulate that the coverage 
indicators are intended to be measured among the target population defined as those at risk for 
malaria.  For countries where malaria is endemic or epidemic-prone throughout, this issue 
should not be of particular concern as long as stratification by urban and rural residency is 
undertaken, as is typically the case with the DHS, MICS, and MIS surveys.  However, within 
countries that contain large populations in areas absent of malaria, such as those with 
mountainous areas or deserts, national-level estimates, such as those obtained from the DHS 
and MICS surveys, will likely result in an underestimate of coverage for those at risk for malaria.  
In such a situation, it may be advisable to collect additional information that can establish 
whether an enumeration area is within or outside a malaria risk area; then during data analysis 
one can limit the analysis to survey domains that are deemed to be malarious.  If this is not 
possible, data should be interpreted accordingly.  
 
Despite the difficulties associated with varying levels of endemicity, progress in malaria 
intervention coverage is generally monitored at the national level in high malaria burden 
countries in Africa, rather than among sub-national at-risk populations.  There are many 
important reasons for relying on national-level estimates of malaria intervention coverage. For 
many countries it is difficult to accurately define at-risk areas and subsequently identify  
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households surveyed within those areas since surveys do not always geo-code the households 
or villages where survey interviews occur [7]. Additionally, the at-risk population will continue to 
change, and therefore it would be difficult to measure progress with the indicators proposed.  
Finally, if a strategy is being implemented in an effort to achieve elimination, high coverage 
levels must be sustained at the national level in order to continue to control malaria and prevent 
against future resurgence of the disease. 
 
Consequently, indicator estimates obtained from DHS and MICS surveys will not be expected to 
correspond specifically to malaria endemic areas, but will be nationally-representative, even in 
those countries with non-malarious regions. The MIS guidelines should be consulted in order to 
incorporate an appropriate subsampling design in those countries which include non-malarious 
regions. 
 
Seasonality 
 
A second consideration that affects the interpretation of the survey findings is the timing of 
survey implementation relative to the malaria transmission season (rainy and early-post-rainy 
seasons).  Generally speaking, MIS surveys are conducted during or immediately after the rainy 
season, and should begin no later than six weeks after the rains end, as this timeframe is 
associated with peak transmission.  However, for operational reasons both DHS and MICS 
surveys are conducted during the dry season and therefore outside of the peak malaria 
transmission period.  As intervention coverage or usage levels may differ significantly between 
seasons, and malaria morbidity and mortality will differ by season, interpretations of the data 
obtained must take into account the seasonality of the survey period.  Further analysis of these 
data is needed to better understand the extent of the relationship between survey timing and 
intervention coverage.  
 
Notes on significant assumptions and potential biases associated with specific indicators are 
provided separately in Section 4 under the description of each indicator.  RBM Working Group                                                              TECHNICAL PAPER – RBM/WG/2009/TP.1 
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4.  Guidelines for Constructing each Core RBM Outcome Indicator  
for Population Coverage 
 
4.1  Vector Control via ITNs 
 
1.  Proportion of Households with at Least One ITN
1 
 
 
  Numerator: Number of households surveyed with at least one ITN. 
 
  Denominator: Total number of households surveyed. 
 
 
 
Purpose 
 
This indicator will be used to measure household ITN possession among the population at the 
national level. 
 
Method of Measurement 
 
This indicator requires data collected at the household level from nationally representative 
sample surveys.  The MIS guidelines should be consulted for guidance on constructing a 
sampling frame and conducting data analyses for countries with varying levels of malaria 
endemicity. It is important that these data be collected on a household questionnaire, rather 
than on an individual questionnaire, as the individuals interviewed may not be representative of 
household possession.  It is also important that surveys be conducted with sufficient design and 
sample size to allow comparisons among regions and urban/rural strata at the household level.  
The numerator for this indicator is obtained from asking household respondent if there is any 
mosquito net in the house that can be used to avoid being bitten while sleeping, and from 
determining whether it is a factory treated net that does not require any treatment, a pretreated 
net obtained within the past 12 months, or a net that has been soaked with insecticide within the 
past 12 months.  The denominator is simply measured by the total number of surveyed 
households. 
                                                 
1 An ITN is 1) a factory treated net that does not require any treatment, 2) a pretreated net obtained within the past 12 
months, or 3) a net that has been soaked with insecticide within the past 12 months.  
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Interpretation 
 
This indicator provides a proxy measure for household ITN use at the national level. 
 
 
Strengths    The limited number of questions required to ascertain data for this indicator can 
be easily added to any nationally representative sample survey of households. 
  Presence of a net is typically verified at time of interview. 
  Comparable across countries given that appropriate and consistent sampling 
procedures are followed and confounding factors are accounted for.  
Limitations    Because of issues of date recall of last impregnation, this indicator may not 
provide reliable estimates of net retreatment status. 
  May be difficult to interpret at the national level unless stratified by urban and 
rural strata as malaria transmission is most often localized.  
  Typically, no information is collected on whether the insecticide used to treat the 
net is an ―approved‖ insecticide. 
  No information is collected on whether the net was washed after treatment, 
which can reduce its effectiveness. 
 RBM Working Group                                                              TECHNICAL PAPER – RBM/WG/2009/TP.1 
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2.  Proportion of Children under 5 Years Old who Slept under an ITN
2  
the Previous Night 
 
 
  Numerator: Number of children under 5 years old who slept under an ITN the previous 
night. 
 
  Denominator: Total number of children under 5 years old who spent the previous night in 
surveyed households. 
 
 
 
Purpose 
 
This indicator will be used to measure the level of ITN coverage of children under 5 years old 
who are at the national level.  
 
Method of Measurement 
 
This indicator requires data collected from nationally representative household sample surveys. 
The MIS guidelines should be consulted for guidance on constructing a sampling frame and 
conducting data analyses for countries with varying levels of malaria endemicity.  It is important 
that the survey contain a household listing that captures all children under 5 years old within 
each surveyed household.  Additionally, surveys should be conducted with sufficient design and 
sample size to allow comparisons among regions and urban/rural strata.  
 
The data for the denominator are obtained from the household questionnaire that lists every 
child under 5 who slept in the house the previous night.  The data for the numerator are then 
obtained from a listing of the same children in the house who slept under a mosquito net the 
previous night, in combination with information on whether it is a factory treated net that does 
not require any treatment, a pretreated net obtained within the past 12 months, or a net that has 
been soaked with insecticide within the past 12 months.   
 
                                                 
2 An ITN is 1) a factory treated net that does not require any treatment, 2) a pretreated net obtained within the past 12 
months, or 3) a net that has been soaked with insecticide within the past 12 months.  
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Interpretation 
 
This indicator provides a direct measure of ITN use by children under 5 years of age at the 
national level. 
 
Strengths    The limited number of questions required to ascertain data for this indicator can 
be easily added to any nationally representative sample survey of households.  
  Presence of a net is typically verified at time of interview.  
  Comparable across countries given that appropriate and consistent sampling 
procedures are followed and confounding factors are accounted for. 
Limitations    Because of issues of date recall of last impregnation, this indicator may not 
provide reliable estimates of net retreatment status. 
  May be difficult to interpret at the national level unless stratified by urban and 
rural strata as malaria transmission is most often localized.   
  May be biased by the seasonality of survey data collection, which is most often 
done during the dry season when net use is likely at its lowest.  
  Typically, no information is collected on whether the insecticide used to treat the 
net is an ―approved‖ insecticide. 
  No information is collected on whether the net was washed after treatment, 
which can reduce its effectiveness. 
 
Supplemental ITN Indicator  
 
ITN Usage among All Age Groups 
Proportion of Individuals who Slept under an ITN the Previous Night 
  
  Numerator: Number of individuals who slept under an ITN the previous night.  
 
  Denominator: Total number of individuals who slept in surveyed households the 
previous night. 
 
In certain instances, calculating the proportion of all household residents using an ITN may 
be deemed necessary.  It is useful to track usage among all ages since coverage of entire 
populations will be required to accomplish large reductions of malaria burden.  While 
vulnerable groups, such as children under 5 years old and pregnant women, should still be 
prioritized, the equitable and communal benefits of wide-scale ITN use by older children and 
adults should be promoted and evaluated by national malaria control programs [37].  
Furthermore, in areas of low endemicity, extending the age group is not only relevant, since 
more cases occur among individuals older than five years than among those under 5 years 
of age, but also sensible since fewer households would have to be visited to obtain the 
desired number of eligible interviewees.  A supplemental ITN indicator would allow ITN 
usage for the entire population to be tracked.  RBM Working Group                                                              TECHNICAL PAPER – RBM/WG/2009/TP.1 
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4.2  Indoor Residual Spraying 
 
3.  Households Covered by Vector Control 
 
Proportion of Households with at Least One ITN
3 and/or Sprayed by IRS in the Last 12 
Months  
 
  Numerator: Number of households that have at least one ITN and/or have been sprayed 
by IRS in the last 12 months. 
 
  Denominator: Total number of households surveyed.  
 
 
 
Purpose/Rationale 
 
This indicator allows overall national coverage of the two main vector control activities to be 
assessed.  It will be used to measure the proportion of households covered by either an ITN or 
by IRS.  In places where IRS is limited to small target areas, this indicator provides a more 
appropriate assessment of the vector control activities being conducted throughout the country 
than an indicator measuring national coverage of IRS activity alone. 
Method of Measurement 
This indicator requires data collected from nationally representative household sample surveys.  
The data for the numerator are obtained from information on which households possess an ITN, 
in combination with information on whether the household has been protected by IRS in the last 
twelve months.  The denominator is simply the total number of households in the survey.  
In those countries which have already begun to gather IRS information through MIS, this 
indicator can be calculated with currently existing survey questions and can be tabulated 
retroactively using past survey data.  However, additional questions will have to be added to 
those survey questionnaires (e.g. DHS, MICS) which have not included questions on IRS in the 
past.  
An IRS campaign may be conducted either as part of the national strategy for malaria control 
(operations conducted by governmental spray teams) or undertaken by an NGO or private 
company.  It is important to capture only those spraying activities that have occurred as part of 
an organized IRS campaign, and to exclude spraying that was conducted by a member of the 
household. 
                                                 
3 An ITN is 1) a factory treated net that does not require any treatment, 2) a pretreated net obtained within the past 12 
months, or 3) a net that has been soaked with insecticide within the past 12 months.  
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Interpretation 
 
This indicator provides a proxy measure of national ITN and IRS coverage. 
 
 
Supplemental IRS Indicators 
 
 
Program-level Indicators 
Reliable program data, obtained during routine spraying activities, is crucial for evaluating the 
performance of IRS programs.  Given that household survey data has limitations such as recall 
bias and results at the national level may be misleading, program data should be collected in 
order to more accurately assess the  progress achieved by spraying programs to date.  To 
facilitate this process, program-level indicators may need to be reported as part of the national-
level monitoring and evaluation plan. 
Two such indicators are outlined in detail in a separate document [18]. 
Strengths    The IRS data for this indicator is already collected during MIS surveys, and the 
limited number of questions required to ascertain this data can be easily added 
to other surveys. 
  Presence of a mosquito net is typically verified at time of interview. 
  This indicator has been developed to address concerns regarding the small 
areas or ‗target zones‘ that are sprayed with IRS in many countries, and the 
potential misinterpretations of a national-level IRS indicator that may result.  By 
including ITN and IRS interventions in a single indicator, one can assess overall 
vector control coverage within the country.  
Limitations    Recall bias is likely to affect this indicator, as the issue of asking respondents to 
recall when the household was sprayed can result in considerable bias and 
‗heaping‘ of dates. 
  Additionally, the actual respondent may not have been present at the time of 
spraying and may therefore be reporting what was heard from others. 
  Estimate may be biased upwards if the respondent confuses spraying with 
residual insecticide with household products; however, such confusion can be 
reduced by thorough training of interviewers. RBM Working Group                                                              TECHNICAL PAPER – RBM/WG/2009/TP.1 
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National-level IRS Indicator 
In addition to the indicator listed above, in countries where sizeable IRS operations are 
underway it may be advantageous to report IRS coverage at the national level.  Data obtained 
from household surveys would be used, and therefore careful interpretation of the results is 
required, since achieving high levels of IRS coverage at the national level is not always the 
intent of programs.  Since the denominator does not specifically include those areas where a 
program has intended to spray, this indicator cannot be used to evaluate the performance of a 
national IRS program.  In some countries, relatively small areas or ‗target zones‘ are specifically 
targeted for spraying, so taking a nationally-representative sample may misrepresent the extent 
to which IRS targets have been achieved, as low nation-wide coverage is not necessarily an 
indication of a poorly-performing IRS program.  However, this data is necessary to collect in 
order to calculate the core indicator listed above.  Furthermore, it may be deemed necessary to 
report on this indicator in certain countries due to reporting requirements, consistency between 
years, and sampling considerations. 
A national-level IRS indicator is outlined in detail on page 25. 
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IRS National-level Indicator 
Proportion of Households which Received Spraying through an IRS Campaign within the 
Last 12 Months  
  Numerator: Number of households that were sprayed with a residual insecticide during an 
IRS campaign in the last 12 months.  
  Denominator: Total number of households surveyed.  
 
Purpose/Rationale 
 
The purpose of this indicator is to measure IRS coverage at the national level.  The intent is to 
obtain information on overall coverage with IRS, rather than information on the quality of spraying 
activities.   
 
Method of Measurement 
 
Household survey questions for measuring population-level IRS coverage from a DHS, MICS, or 
MIS survey can be used to obtain the necessary information.  This indicator can therefore be 
constructed from any household survey which includes such questions and covers areas where 
spraying is expected to have occurred. 
An IRS campaign may be conducted either as part of the national strategy for malaria control 
(operations conducted by governmental spray teams) or undertaken by an NGO or private 
company (operations conducted independent of the national strategy).  It is important to capture 
only those spraying activities that have occurred as part of an organized IRS campaign rather 
than spraying that was conducted by a member of the household.   
The ideal household survey would be a MIS which has coverage sufficient to include a large 
proportion of all areas intended for spraying by the national program.  If the household survey 
used for collecting data for this indicator does not specifically use a survey population defined as 
those at risk for malaria, care must be taken to ensure a sufficient sample size is obtained within 
malaria endemic areas of the country.  It may also be necessary to over-sample within certain 
districts with known levels of malaria transmission, and known levels of IRS activity, for 
comparison purposes and to aid with interpretation. 
 
Interpretation 
 
This indicator provides a proxy measure of IRS coverage at the national level over a 12-month 
time period.  
Strengths 
 
  General coverage indicator that provides a national program with an estimate of the proportion of all 
households that report that their household has been sprayed.  
  12 month timeframe captures spraying prior to rainy season. 
Limitations 
 
  Recall bias is likely to affect this indicator, since asking respondents to recall when the household was 
sprayed can result in considerable bias and ‗heaping‘ of dates. 
  Additionally, the actual respondent may not have been present at the time of spraying and may 
therefore be reporting what was heard from others. 
  Estimate may be biased upwards if the respondent confuses spraying with residual insecticide with 
household products; however, such confusion can be reduced by thorough training of interviewers. RBM Working Group                                                              TECHNICAL PAPER – RBM/WG/2009/TP.1 
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4.2  Prompt Diagnosis and Effective Treatment (among children and 5 years old) 
 
4.   Proportion of Children under 5 Years Old with Fever in Last 2 Weeks  
who Received Any Antimalarial Treatment  
 
 
  Numerator: Number of children under 5 years old who had a fever in previous 2 weeks 
  who received any antimalarial treatment. 
 
  Denominator: Total number of children under 5 years old who had a fever in previous  
  2 weeks. 
 
Purpose 
 
This indicator captures the national-level access to antimalarial treatment for malaria.  
 
Method of Measurement 
 
This indicator requires data collected from nationally representative household sample surveys.  
The MIS guidelines should be consulted for guidance on constructing a sampling frame and 
conducting data analyses for countries with varying levels of malaria endemicity.  
 
The data for the denominator are obtained in one of two ways, depending on the type of survey 
used.  Some surveys use the household listing procedure when every child under 5 who slept in 
the house the previous night is identified (MICS).  Other surveys ask questions in the women‘s 
questionnaire about all of their children under the age of 5, thus the denominator includes the 
children of women of reproductive age (who slept in the house the night before the survey) who 
had a fever in the previous two weeks.  The numerator is then obtained by asking all mothers 
and/or caregivers (depending on survey method) in the household whether any of the children 
who had a fever in the past 2 weeks were given an antimalarial treatment.  
 
Nearly all countries in SSA have shifted their national drug policies to highly effective 
artemisinin-based combination therapies; however, a large proportion of children with fever are 
still treated with less effective traditional monotherapies. This indicator captures children 
receiving such treatment.  Consequently, the proportion of children treated with any antimalarial 
will be significantly higher than the proportion treated with effective antimalarials. Therefore, this 
indicator should be carefully interpreted.  
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Interpretation 
 
This indicator provides a proxy measure of national ITN and IRS coverage. This indicator 
provides a proxy measure for the level of access of children under 5 years old to treatment for 
malaria infections, at the national level.  
 
 
Strengths    The limited number of questions required to ascertain data for this 
indicator can be easily added to any nationally representative sample 
survey of households. 
  Comparable across countries given that appropriate and consistent 
sampling procedures are followed and confounding factors are 
accounted for. 
Limitations    Fever may not have been the result of malaria infection. 
  Because of issues of date recall, indicator may not provide reliable 
estimates of episodes of fever within previous 2 weeks or the identity of 
which specific drug was given. 
  There is no way of knowing if antimalarial treatments were administered 
correctly. 
  Data based solely on the mother‘s or caretaker‘s information may miss 
fostered children or others living in a household without a 
parent/caretaker. 
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5.  Proportion of Children under 5 Years Old with Fever in Last 2 Weeks who 
Received Antimalarial Treatment According to National Policy within 24 Hrs  
from Onset of Fever 
 
 
  Numerator: Number of children under 5 years old who had a fever in previous 2 weeks 
who received recommended antimalarial treatment according to national policy <24 hours 
from onset of fever.  
 
  Denominator: Total number of children under 5 years old who had a fever in previous 2 
weeks. 
 
 
 
Purpose 
 
This indicator captures the national-level access to prompt and effective treatment for malaria.  
Prompt and effective treatment within 24 hours of the onset of symptoms is necessary to 
prevent life-threatening complications [7].  
Method of Measurement 
 
This indicator requires data collected from nationally representative household sample surveys.  
The MIS guidelines should be consulted for guidance on constructing a sampling frame and 
conducting data analyses for countries with varying levels of malaria endemicity.  
 
The data for the denominator are obtained in one of two ways, depending on the type of survey 
used.  Some surveys use the household listing procedure when every child under 5 who slept in 
the house the previous night is identified (MICS).  Other surveys ask questions in the women‘s 
questionnaire about all of their children under the age of 5, thus the denominator includes the 
children of women of reproductive age (who slept in the house the night before the survey) who 
had a fever in the previous two weeks.  The numerator is then obtained by asking all mothers 
and/or caregivers (depending on survey method) in the household whether any of the children 
who had a fever in the past 2 weeks were given an antimalarial treatment.  
 
The specific drug given and the timing of treatment relative to the onset of fever must also be 
recorded.  The appropriate treatment to be used depends on the local drug efficacy spectrum, 
and is operationally defined as all first-line antimalarial drugs that were included in the national 
drug policy for treatment of uncomplicated pediatric malaria at the time the survey was 
conducted.  
Since 2003, nearly all countries in SSA have shifted their national drug policies to highly 
effective ACTs.  Consequently, the region has entered a dynamic transition period, shifting from 
conventional antimalarial monotherapies to ACTs.  As such, present-day delivery of 
antimalarials is likely to be a combination of newly-recommended ACTs and previously-used 
monotherapies.  Hence, the figures reported for this indicator may be low initially, but will likely 
increase as financing, procurement, and delivery of ACTs continues to increase [7].  
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The reference to ‗effective treatment‘ above is not intended to mean the effectiveness of a 
dosing regimen.  Rather, this indicator is meant to assess program coverage: at a minimum, 
children should be treated with those drugs included in the national antimalarial drug policy.  
While it is not possible to truly measure the effectiveness of the treatment delivered, whether 
children receive those drugs recommended for malaria treatment does measure one factor 
contributing to effectiveness.  
 
Interpretation 
 
This indicator provides a proxy measure for the level of access of children under 5 years old to 
prompt and effective treatment for malaria infections, according to national guidelines, at the 
national level. 
 
Strengths    The limited number of questions required to ascertain data for this indicator can 
be easily added to any nationally representative sample survey of households. 
  Comparable across countries given that appropriate and consistent sampling 
procedures are followed and confounding factors are accounted for. 
Limitations    Fever may not have been the result of malaria infection. 
  Because of issues of date recall, indicator may not provide reliable estimates of 
episodes of fever within previous 2 weeks, the length of time after onset of fever 
before an antimalarial drug was given, or the identity of which specific drug was 
given. 
  There is no way of knowing if antimalarial treatments were administered 
correctly. 
  Data based solely on the mother‘s or caretaker‘s information may miss fostered 
children or others living in a household without a parent/caretaker. 
  May be difficult to compare across countries with different antimalarial drug 
policies; however, many countries have now adopted guidelines which 
recommend use of artemisinin-based combination therapy, resulting in greater 
consistency between policies. 
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6.  Proportion of Children under 5 Years Old with Fever in Last 2 Weeks who had a 
Finger or Heel Stick  
 
 
  Numerator: Number of children under 5 years old who had a fever in the previous 2 weeks 
who had a finger/heel stick. 
 
  Denominator: Total number of children under 5 years old who had a fever in the previous 
2 weeks. 
 
Purpose 
 
The replacement of conventional antimalarial drugs with high-cost, artemisinin-based 
alternatives has created an increased need for accurate disease diagnosis.  In addition to 
avoiding unnecessary treatment with these expensive drug combinations, diagnostics allow a 
more rational use of drugs that might effectively reduce drug pressure, thereby delaying the 
onset of drug resistance.  This indicator is intended to capture baseline-level coverage and 
subsequent scale-up of diagnostic programs. 
Method of Measurement 
 
This indicator requires data collected from nationally representative household sample surveys.  
The MIS guidelines should be consulted for guidance on constructing a sampling frame and 
conducting data analyses for countries with varying levels of malaria endemicity.  
 
The data for the denominator are obtained in one of two ways, depending on the type of survey 
used.  Some surveys use the household listing procedure when every child under 5 who slept in 
the house the previous night is identified (MICS).  Other surveys ask questions in the women‘s 
questionnaire about all of their children under the age of 5, thus the denominator includes the 
children of women of reproductive age (who slept in the house the night before the survey) who 
had a fever in the previous two weeks.  The numerator is then obtained by asking all mothers 
and/or caregivers in the household whether any of the children who had a fever in the past 2 
weeks received a finger/heel stick.  
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Interpretation 
 
This indicator provides a proxy measure for the level of access of children under 5 years old to 
diagnostics for malaria infections, at the national level.   
 
 
Strengths    The limited number of questions required to ascertain data for this indicator can 
be easily added to any nationally representative sample survey of households. 
  Comparable across countries given that appropriate and consistent sampling 
procedures are followed and confounding factors are accounted for. 
Limitations    Because of issues of date recall, indicator may not provide reliable estimates of 
episodes of fever within previous 2 weeks. 
  Fever may not have been the result of malaria infection. 
  Finger/heel stick may not have been conducted to diagnose malaria (for 
instance, these methods are also used to diagnose anemia).  However, the 
most likely purpose for this age group is malaria testing, especially subsequent 
to fever, so this should not be of considerable concern.  The mother is not 
specifically asked whether the finger/heel stick was conducted for malaria 
testing due to concerns that an underestimate would result, as some women 
may not know whether the sample drawn was used for malaria diagnosis. 
  Data based solely on the mother‘s or caretaker‘s information may miss fostered 
children or others living in a household without a parent/caretaker. 
 
Additional Note: Presumptive Treatment Recommendations 
In high and moderate malaria transmission areas where infection is common, the World Health 
Organization recommends that all children under the age of five with fever be treated with 
antimalarial medicines based on a clinical diagnosis—that is, presumptively, based on 
presentation of the signs and symptoms of the disease [7]. 
Malaria is usually the most common cause of fever in children under 5 years of age in stable 
high-transmission settings. Antimalarial treatment should therefore be given to children with 
fever (>37.5°C) or a history of fever and no other obvious cause.  Malaria is the most likely 
cause of their illness and there is as yet no evidence to show that the benefits of parasitological 
diagnosis in this highly vulnerable group outweigh the risks of not treating false negatives.  In 
high-transmission settings, all under-5 children with a clinical suspicion of malaria should 
therefore be treated [38]. 
In light of these recommendations, high levels of diagnostic use among under 5 year olds may 
not be a priority in certain countries.  In such cases, the proportion of children receiving a finger 
or heel stick is expected to be low, and this should not be interpreted as a poorly-performing 
program as diagnostics may not yet be intended for wide-scale use.  However, as this 
intervention is rolled out across countries, the indicator values reported are expected to 
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4.4  Prevention & Control among Pregnant Women 
 
7.  Proportion of Pregnant Women Who Slept Under an ITN
4 the Previous Night 
 
 
  Numerator: Number of pregnant women who slept under an ITN the previous night. 
 
  Denominator: Total number of pregnant women within surveyed households. 
 
 
 
Purpose 
 
This indicator will be used to measure the level of ITN use by pregnant women at the national 
level.  
 
Method of Measurement 
 
This indicator requires data collected from nationally representative household sample surveys.  
The MIS guidelines should be consulted for guidance on constructing a sampling frame and 
conducting data analyses for countries with varying levels of malaria endemicity.  Because of 
the small number of currently pregnant women at any given time, a survey designed to collect 
these data should have an overall sample of ≥5,000 women (to be comparable with DHS 
surveys).  Note that the MICS survey does not currently collect data for this indicator because it 
does not collect data on currently pregnant women. 
 
The data for the denominator are obtained from a series of questions asked of all women of 
reproductive age in the household about their current pregnancy status.  The data for the 
numerator are then obtained from a listing of these women that slept under a mosquito net the 
previous night, in combination with information on current pregnancy status and whether the net 
is a factory treated net that does not require any treatment, a pretreated net obtained within the 
past 12 months, or a net that has been soaked with insecticide within the past 12 months.  
                                                 
4 An ITN is 1) a factory treated net that does not require any treatment, 2) a pretreated net obtained within the past 12 
months, or 3) a net that has been soaked with insecticide within the past 12 months.  
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Interpretation 
 
This indicator provides a direct measure of ITN use by pregnant women at the national level. 
 
Strengths    The limited number of questions required to ascertain data for this indicator can 
be easily added to any nationally representative sample survey of households.  
  Presence of a net is typically verified at time of interview.  
  Comparable across countries given that appropriate and consistent sampling 
procedures are followed and confounding factors are accounted for. 
Limitations    Difficult to capture all pregnant women in a household survey because many 
women either don‘t know they are pregnant or do not want to divulge this 
information during early pregnancy.  
  Large sample size required to obtain precise estimates. 
  May be some bias if reluctance to discuss pregnancy is also associated with 
first births, adolescents, and other demographic factors.  
  May be difficult to interpret at the national level unless stratified by urban and 
rural strata as malaria transmission is most often localized.   
  May be biased by the seasonality of survey data collection, which is most often 
done during the dry season when net use is likely at its lowest.  
  Typically, no information is collected on whether the insecticide used to treat the 
net is an ―approved‖ insecticide. 
  No information is collected on whether the net was washed after treatment, 
which can reduce its effectiveness. 
  May be misleading at the national level as transmission is most often localized. 
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8.  Proportion of Women who Received Intermittent Preventive Treatment (IPT)   During 
Antenatal Care (ANC) Visits during Their Last Pregnancy  
 
 
  Numerator: Number of women who received two or more doses of a recommended 
antimalarial drug treatment during ANC visits to prevent malaria during their last 
pregnancy that led to a live birth within the last 2 years.  
 
  Denominator: Total number of women surveyed who delivered a live baby within the last 
2 years. 
 
Purpose 
 
The World Health Organization recommends that all pregnant women in areas of stable malaria 
transmission receive at least two doses of IPT during regularly scheduled antenatal visits under 
direct observation of a health worker [39].  This indicator will be used to measure the national-
level use of IPT to prevent malaria during pregnancy among women. 
Method of Measurement 
 
This indicator requires data collected from nationally representative household sample surveys.  
The MIS guidelines should be consulted for guidance on constructing a sampling frame and 
conducting data analyses for countries with varying levels of malaria endemicity.  Additionally, 
because of the limited number of women who delivered a live baby within the previous 2 years, 
care should be taken to ensure surveys are conducted with sufficient sample size and designed 
to allow comparisons among regions and urban/rural strata at the individual level. 
 
Data from the women‘s questionnaires for all women who delivered a live baby within the last 
2 years within surveyed household is used to calculate the denominator.  The numerator is 
derived from the number of women who mention taking an antimalarial for prevention (not 
treatment) during their most recent pregnancy (from among all listed births to women in the last 
2 years).  Note that in the DHS and MIS surveys, data from the women‘s questionnaire includes 
all births within the previous 5 years, from which the child‘s date of birth can be used to limit 
these to the last pregnancy that resulted in a live birth within the previous 2 years. 
 
The currently recommended drug for IPT is SP.  In order to obtain accurate data for this 
indicator, it is also important to differentiate between a treatment dose for prevention (as 
prescribed for IPT) and actual treatment of an existing malaria infection.  Although it is 
extremely difficult to differentiate in the context of a survey interview, the latter is curative care, 
and does not count as standard IPT procedure.  Similarly, women taking weekly chloroquine 
prophylaxis are not considered to be covered by IPT.  
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Interpretation 
 
This indicator provides a measure for the proportion of pregnant women who receive IPT during 
pregnancy, at the national level. 
 
Strengths    The limited number of questions required to ascertain data for this indicator 
can be easily added to any nationally representative sample survey of 
households. 
  Comparable across countries given that appropriate and consistent sampling 
procedures are followed and confounding factors are accounted for. 
  Provides a measure of program coverage, as IPT is to be administered during 
ANC. 
Limitations    Retrospective questions about IPT given during previous pregnancy may be 
subject to recall bias.  
  Does not provide information regarding which stage during pregnancy IPT was 
given. 
  May be misleading at the national level as malaria transmission is most often 
localized. 
  May not provide reliable estimates for what type of antimalarial was given 
because of poor recall. 
  Household surveys may under-report the current level of IPT administered due 
to the fact that IPT is a relatively recent introduction in many countries and 
therefore women experiencing pregnancies two years prior to the survey are 
less likely to have had access to IPT than those women experiencing 
pregnancies more recently. 
Supplemental Indicator 
 
 
HMIS as an Alternative Data Source 
 
The primary disadvantage of surveys is that their results refer to pregnancies that occurred up 
to two years prior to the time of the survey, and hence provide outdated estimates.  However, 
measurement through HMIS captures IPT at the current time, and analyses can be targeted to 
facilities where IPT is actually being implemented.  Consequently, it may be appropriate to 
collect data through both sources in certain cases.  An IPT indicator to be obtained from ANC 
registers is provided in the Global Fund M&E Toolkit  
(http://www.theglobalfund.org/en/performance/monitoring_evaluation/).   
 
This indicator provides an alternative measure of ITP delivered through ANC.  It is important to 
note that a different denominator is used in the calculation of this indicator; consequently, direct 
comparisons cannot be made between this indicator and the RBM core indicator described 
above.  
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5.  Guidelines for Constructing Each Core RBM Impact Indicator  
 
9.  All-Cause under 5 Mortality Rate  
 
Purpose/Rationale 
To evaluate the impact of interventions, all-cause under 5 mortality trends should be assessed 
in malarious countries.  In areas of stable endemicity, the major burden of malaria occurs in very 
young children who, because they have not yet developed adequate clinical immunity, are at 
highest risk of severe illness and death.  Among malaria deaths in all ages, an estimated 64 to 
90% occur in under 5 year olds.  
Method of Measurement 
 
The under 5 mortality rate (U5MR) can be derived from household survey data using direct or 
indirect methods.  The direct method is used with DHS surveys and requires data collected on 
the birth date and either death date or age at death of non-surviving children in order to produce 
the probability of dying before age five from children exposed to mortality during the five year 
period before the survey.  More specifically, the DHS employs the synthetic cohort life table 
approach, in which mortality probabilities for small age segments based on real cohort mortality 
experience are combined into larger age segments that correspond to the age group of interest. 
In the case of MICS surveys, under 5 mortality rates are calculated based on an indirect 
estimation technique known as the Brass method.  This technique converts the proportion dead 
of children ever born reported by women in age groups 15-19, 20-24,…., 45-49 into estimates of 
probability of dying before attaining certain exact childhood ages.  By using model life tables 
and strong assumptions as to age patterns and time trends, the mortality rate estimates are 
indirectly derived as well as the date to which they apply. 
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Interpretation 
 
This indicator provides a measure of all-cause under 5 mortality, at the national level. 
 
 
Strengths    All-cause mortality can be measured reliably, and does not suffer from limitations 
of methods to identify malaria-specific deaths. 
  Is representative of large populations of interest 
  Captures direct and indirect malaria impacts of mortality. 
Limitations    Due to cost and other resource limitations, large nationally representative 
surveys are usually conducted on either three year or five year cycles, and 
therefore data may not be available at the optimal intervals for evaluation. 
  The survey recall period may not coincide exactly with the scale-up period of 
interventions, causing their impact to be underestimated. 
  Household surveys calculate mortality rates over a five-year period to make sure 
there are enough cases to produce reliable results. Therefore, on average, 
surveys measure under-five mortality with a 2-1/2 year lag. 
  If malaria-specific mortality decreases by 50%, a 15-19% reduction in all-cause 
under 5 mortality is expected; however, at the usual sample size, DHS surveys 
can statistically confirm under-five mortality reductions between two successive 
surveys if the true mortality reduction is 15% or larger. Consequently, the ability 
to detect a reduction in all-cause mortality resulting from fairly small reductions in 
malaria deaths may be difficult when relying on this data source.  
  Due to use of the indirect method, MICS surveys are unable to detect changes in 
age-patterns of child mortality. 
 
Supplemental Impact Indicator 
 
Malaria-Specific Mortality 
In some cases, verbal autopsies attached to household surveys may be able to provide 
information on malaria-specific mortality.  Verbal autopsy is a method for determining cause of 
death by conducting interviews with the deceased child‘s relatives, during which they are asked 
about the signs and symptoms of the child‘s terminal illness.  Verbal autopsies can be 
performed either by adding questions to a mortality survey or sending interviewers after the 
survey to those households in which deaths were identified.  This survey-linked approach 
provides a nationally representative measure of malaria-attributable mortality.  However, 
operational research is needed to assess and improve these methodologies, as these methods 
may present challenges at the national level [7].  Therefore, it is recommended that the 
emphasis remains on monitoring trends in all-cause under 5 mortality at this time. 
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10.  Parasitemia Prevalence 
Proportion of Children Aged 6-59 Months with Malaria Infection  
(To be obtained from household surveys and not from HMIS data)  
 
  
 
  Numerator: Number of children aged 6-59 months with malaria infection detected by 
microscopy. 
 
  Denominator: Total number of children aged 6-59 months tested for malaria parasites by 
microscopy. 
 
 
Purpose/Rationale 
 
The prevalence of parasitemia is a useful indicator of malaria burden.  With intervention 
coverage data and repeated estimation, our understanding of the epidemiology of malaria can 
be improved and progress of control efforts can be tracked more effectively if estimates of 
parasitemia prevalence are available. 
 
Method of Measurement 
 
Parasitemia testing should be included in surveys that are conducted during the high 
transmission season for malaria.  In some cases where transmission is perennial, seasonal 
peaks may still influence the prevalence in parasitemia and seasonality should be taken into 
account for planning.  The MIS should ideally be conducted toward the end of the rainy season.  
This timeframe is associated with peak transmission and therefore is suitable for inclusion of 
parasitemia measurement.  Large-scale household surveys are typically not suitable for 
inclusion of parasitemia because these surveys are not usually conducted during the high 
transmission season and because of the length of fieldwork, which would cover different periods 
of seasonal transmission.   
 
Parasitemia testing should target children between the ages of six months and fifty-nine months.  
This is the same age range that is targeted for testing for anemia in both DHS and MIS surveys.  
Prevalence of parasitemia should be based on microscopically examined blood films prepared 
in the field and read in a quality-controlled laboratory by well-trained microscopists.  Thick blood 
films will be sufficient where P. falciparum is dominant but where species determination is 
required to estimate levels of infection with P. vivax or other species, thin films are also 
warranted.  While rapid diagnostic tests should be included for field detection of infected 
individuals, all of whom should be treated or referred according to national policy, microscopy is 
currently the recommended method for laboratory confirmation and estimation of parasitemia 
prevalence. 
Microscopy and RDTs 
It is important to recognize the distinction between diagnosis in clinical settings and identification 
of infected individuals for prevalence studies where symptoms are not taken into account.  
RDTs are recommended for conducting the former, but not the latter at this point in time.  RDTs 
offer a useful alternative to microscopy in situations where reliable microscopic diagnosis is not 
available, as is often the case in the field. However, several issues concerning the widespread 
use of RDTs still remain to be addressed, including their accuracy, their cost, and their  
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performance under adverse field conditions.  Micropscopy, too, presents special issues for 
survey efforts. Field teams must be adequately trained to collect specimens, mount slides, and 
read results. The storage and transportation of slides is also difficult in the field and requires 
logistical planning. Supervision of these efforts is also important.  Consequently, while the use 
of RDTs to treat individuals in the field is encouraged, microscopy remains the standard for 
measuring parasitemia prevalence at the time of this publication.  If the use of RDTs is 
recommended for estimation of population prevalence in the future, it will be important to 
consider how best to derive prevalence estimates and make reliable comparisons between 
results obtained from different methods. 
Interpretation 
This indicator provides a direct measure of parasitemia prevalence among children aged 6-59 
months, at the national level. 
Strengths    Most malaria impact measures are indirect measures; whereas parasite 
prevalence is a direct, malaria-specific measure.  
  Parasitemia prevalence among children aged 6-59 months is a useful indicator of 
transmission intensity, which in turn is one of the determinants of disease 
incidence. 
Limitations    Some studies of malaria interventions showing mortality reductions have found 
large decreases in parasite prevalence; however, other studies of control 
interventions have found that despite reductions in mortality, parasite prevalence 
changes little.  
  Microscopy is associated with certain inherent limitations: practical difficulties of 
preparing and staining blood films in the field, transportation and storage issues, 
availability of sufficiently trained microscopists (especially in settings where 
speciation is required), and inconsistencies in reading slides.  Despite these 
limitations, this is still the most reliable technology currently available, and the 
permanent record provided by blood films is extremely valuable. 
 
 
Supplemental Indicator 
 
Parasitemia Prevalence among Adults and Pregnant Women 
 
It is not recommended that parasite prevalence be estimated for pregnant women on a regular 
basis because of the large number of households that would need to be included to obtain a 
sufficient sample size and because of the complexities of treating parasite-positive pregnant 
women in the field.  However, in some cases the inclusion of all ages for testing may be 
warranted.  These include surveys scheduled when countries are aiming for elimination, surveys 
that will provide for modeling of incidence of malaria, or surveys conducted when prevalence is 
very low.  Recruitment of an older, less accessible population and treatment of pregnant 
women, especially early pregnancies which are more difficult to detect, should be weighed 
against the benefits of testing all ages.  In sum, one should proceed cautiously when 
considering extending this indicator to respondents of all ages, but under the above 
circumstances special studies may be deemed appropriate and a supplemental indicator should 
then be calculated. 
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11.  Anemia Prevalence 
 
Proportion of Children Aged 6-59 Months with a Hemoglobin Measurement  
of < 8 g/dL  
 
 
  Numerator: Number of children aged 6-59 months with a hemoglobin measurement of < 8 
g/dL. 
 
  Denominator: Total number of children aged 6-59 months who had hemoglobin 
measurements obtained during household survey. 
 
Purpose/Rationale 
Anemia, defined by a hemoglobin (Hb) concentration below established cut-off levels, is a 
widespread public health problem.  It is useful to follow trends in anemia prevalence, as it is a 
reliable indicator of malaria morbidity that can reflect the impact of malaria interventions [34, 35].  
Malaria interventions have been associated with a 60% reduction in the risk of moderate-to-
severe anemia (Hb < 8 g/dL) [34]. 
Method of Measurement 
Monitoring of anemia through household surveys has become a more viable option due to the 
development of the HemoCue® test of fingerprick blood, which is used to measure Hb 
distributions in large-scale household surveys.  Anemia should be measured in children 6-59 
months old. Surveys should record hemoglobin measurements to the 0.1g/dL precision level 
using HemoCue on capillary blood sampled while the child is sitting [35]. 
 
When classifying nutritional anemia, Hb concentrations are categorized according to criteria 
developed by the World Health Organization [40, 41].  The hemoglobin cut-offs that are used to 
classify nutritional anemia are as follows: severe anemia is diagnosed when the Hb 
concentration is less than 7.0 g/dL; moderate anemia when the hemoglobin concentration is 7.0 
to 9.9 g/dL; and mild anemia when the Hb concentration is 10.0 to 10.9 g/dL in children.  
However, a different cut-off is used to classify malaria-related anemia.  In this case, an Hb 
concentration less than 8 g/dL, which corresponds to moderate-to-severe anemia, is the cut-off 
level that should be used.  
 
This indicator will measure the prevalence of Hb levels below 8g/dL, as intervention trials have 
shown that malaria control reduces the prevalence of moderate-to-severe anemia (e.g. below 
8g/dL) more so than it reduces the prevalence of milder anemia (e.g. below 11g/dL) [34].  
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Interpretation 
 
This indicator provides a proxy measure of the prevalence of malaria-related anemia among 
children aged 6-59 months, at the national level. 
 
 
Strengths    Anemia morbidity is an important health statistic to track on its own, as it is an 
indicator of both poor nutrition and poor health. 
  There is a shortage of reliable indicators that can be used to measure malaria 
impact in the field.  Anemia provides such an indicator, as it can be measured 
using a standard technique due to the HemoCue technology now available. 
  Anemia measurement has become a standard component of DHS surveys and 
some other household surveys.  However, it should be noted that DHS surveys 
include anemia measurements in the nutrition chapter, using the cut-off values 
listed above rather than 8 g/dL, necessitating that caution be taken when 
interpreting and comparing results. 
Limitations    A potential drawback is the seasonal variation in malaria-related anemia, which 
makes survey outcomes sensitive to the season of measurement. 
  Use of anemia as a malaria indicator in areas with low malaria transmission will 
inevitably be compromised by a lack of specificity, given other anemia 
determinants like pediatric HIV/AIDS, malnutrition, and helminth infections.  Even 
in areas of intense malaria transmission, anemia in young children may depend 
more on malnutrition than on malaria, and separating malnutrition from malaria as 
the cause of anemia is not possible as the proportions will vary from population to 
population and cannot be know.  Consequently, data must be interpreted 
cautiously, with consideration of the many other causes of anemia present in the 
survey area. 
 
Supplemental Indicator 
 
 
Survey reports should tabulate both the prevalence of Hb <8g/dL and the mean hemoglobin 
level, preferentially with its standard deviation, so that the user can derive anemia prevalences 
with alternative cut-offs by applying a Normal approximation [35].  In survey reports which 
include sections on both nutrition and malaria, the prevalence of Hb <7 g/dL and the prevalence 
of Hb <8g/dL should be reported in the appropriate chapters.  Consequently, analyses using 
both Hb cut-offs will need to be conducted.  Furthermore, it should be clearly stated in the text 
that the first is measuring severe anemia in order to assess nutritional deficiencies, while the 
second is measuring moderate-to-severe anemia in order to assess the impact of interventions 
on malaria-related anemia. 
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